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Objective To investigate whether repeat courses of antenatal corticosteroids have long-term effects on cognitive
and psychological functioning.
Study design In a prospective cohort study, 58 adolescents and young adults (36 males) who had been exposed
to 2-9 weekly courses of betamethasone in utero were assessed with neuropsychological tests and behavior
self-reports. Unexposed subjects (n = 44, 25 males) matched for age, sex, and gestational age at birth served as
a comparison group. In addition, individuals exposed in utero to a single course (n = 25, 14 males) were included
for dose-response analysis. Group differences were investigated using multilevel linear modeling.
ResultsMean scores obtained in 2 measures of attention and speed were significantly lower in subjects exposed
to 2 or more antenatal corticosteroids courses (Symbol Search, P = .009; Digit Span Forward, P = .02), but these
were not dose-dependent. Exposure to repeat courses of antenatal corticosteroidswas not associatedwith general
deficits in higher cognitive functions, self-reported attention, adaptability, or overall psychological function.
Conclusions Although this study indicates that repeat exposure to antenatal corticosteroids may have an impact
onaspectsof executive functioning, it does notprovidesupport for theprevailing concern that such fetal exposurewill
have a major adverse impact on cognitive functions and psychological health later in life. (J Pediatr 2013;163:441-6).
A
dministration of antenatal corticosteroids to women at risk of premature delivery is common and has proven benefits for
preterm infants.1,2 There is compelling evidence that a single course of antenatal corticosteroids significantly reduces
neonatalmortality and severe neonatalmorbidity (such as respiratory distress and intraventricular hemorrhage)without
adverse long-term effects.3-5 In contrast, controversy exists as to whether the practice of repeating corticosteroids every 7-14 days
for womenwho remain undelivered is beneficial or not. Large randomized controlled trials have reported conflicting results. The
Australasian Collaborative Trial of Repeat Doses of Steroids Study Group found that repeat courses reduced neonatal morbid-
ity,6 and the Multiple Courses of Antenatal Corticosteroids for Preterm Birth Collaboration Group and National Institute of
Child Health and Human Development Maternal-Fetal Medicine Units Network could not confirm improved preterm birth
outcomes after repeat corticosteroid courses.7,8 However, repeat treatments were associated with decreased weight,6-8 length,7
and head circumference at birth.6,7 The latest Cochrane review concluded that repeat courses of corticosteroids were associated
with a reduction in the incidence and severity of neonatal lung disease and a small reduction in size at birth.9
Glucocorticoid receptors are expressed in the human fetal brain and, therefore, high doses of synthetic glucocorticoids
(eg, dexamethasone and betamethasone) could adversely affect the developing brain.10 Studies from nonhuman primate
models indicate that fetal glucocorticoid overexposure can cause abnormal development of motor, affective, and cognitive
behaviors.11
Previous studies have followed exposed children up to 6 years of age and found that children exposed to repeat courses
of antenatal corticosteroids were not different in general cognitive abilities compared with those in placebo control
groups.12-15 However, the Australasian Collaborative Trial of Repeat Doses of Steroids Study Group found that a higherFrom the 1Department of Psychology Stockholm
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 163, No. 2test this hypothesis, a prospectively identified Swedish peri-
natal cohort of adolescents and young adults who had been
exposed to at least 2 and up to 9 courses of antenatal cortico-
steroids, was thoroughly assessed and compared with an un-
exposed reference group. An additional group who had been
exposed to a single course of antenatal corticosteroids was
also included to assess potential dose-response effects.
Methods
All participants in this study were born at Danderyd Hospi-
tal, Stockholm, Sweden, between the years 1983-1996. The
cohort has been described in a previous study, focusing on
the effect of antenatal corticosteroids on size at birth.16 The
standard antenatal corticosteroid treatment consisted of an
initial course of betamethasone 24 mg intramuscularly (8
mg q 8 h), followed by weekly courses of 12 mg betametha-
sone continued until delivery or until pregnancy reached
34 gestational weeks. From a prospectively collected hospital
registry including all mothers undergoing antenatal care and
all infants admitted for neonatal care, we identified 94 infants
exposed to repeat courses of antenatal corticosteroids. Dur-
ing the entire study period, there were standard protocols
for serial ophthalmologic screening of all infants born before
32 weeks of gestation. Serial cranial ultrasound was intro-
duced a few years into the study period. Predefined exclusion
criteria included maternal steroid use for other medical con-
ditions and fetal anomalies, congenital viral infections, and
chromosomal aberrations. In the cohort, the majority were
born moderately preterm or at term, and there were no sub-
jects who suffered from significant intraventricular hemor-
rhage or who developed periventricular leukomalacia. One
subject suffered from retinopathy of prematurity.16
Four of the 94 subjects exposed to repeat corticosteroid
courses could not be found or had moved from Sweden by
the time of follow-up. The remaining 90 were invited to par-
ticipate. To get an age- and sex-matched reference group of
unexposed subjects, we identified 103 subjects born at the
same gestational age as the study group from the hospital’s
birth registry. For dose-response analyses, we also included
a group of subjects exposed to a single course of antenatal
corticosteroids (n = 48) by using the same criteria as for
the reference group. Subjects in the single-course group
were born prior to the administration of the second course,
and, as a result, the group was slightly more preterm than
the other groups. In total, 241 participants were invited to
the follow-up. Of these 127 accepted and were assessed ac-
cording to the protocol. Characteristics of the mothers, preg-
nancies, and participants (neonatal and at follow-up) are
presented in Table I. Participation among exposure groups
differed significantly (c22 = 9.10, P = .01); 64.4% of those
exposed to 2 or more courses, 42.7% of the unexposed, and
52.0% exposed to a single course participated. Those who
declined to participate in the study (n = 114) did not differ
from participants with regards to maternal, pregnancy, or
infant characteristics apart from nonparticipants being
slightly smaller as indicated by birth weight SDS (Mpart =4420.4 vs Mnon-part = 0.8; P = .03; Table II available at
www.jpeds.com)
The neuropsychological test battery included tests from
Wechsler scales (Wechsler Intelligence Scale for Children
[WISC]-III and Wechsler Adult Intelligence Scale
[WAIS]-III, Swedish versions),17,18 from Delis-Kaplan Exec-
utive Function System,19 and the Cambridge Neuropsycho-
logical Test Assessment Battery.20 The tests, grouped into 5
broadly defined domains, included the following: (1) gen-
eral cognitive ability; (2) memory and learning; (3) working
memory; (4) attention and speed; and (5) cognitive flexibil-
ity and inhibition. The last 3 domains reflect executive
functions.
All tests were administered and scored in accordance
with manual instructions. All participants were assessed be-
tween October 2008-April 2010 by the same psychologist
(J.S.) who was blinded to exposure group and gestational
age at birth. The assessments were performed in the same
room and at approximately same time of the day. Measures
on psychological health were obtained from the following
self-report forms: the Achenbach Adult or Youth Self-re-
ports21,22; the World Health Organization’s screen for at-
tention deficit hyperactivity disorder23; and a quality of
life inventory.24 All participants signed informed consent
forms. Participants under the age of 15 were required to
have their legal guardian’s signature. The study was ap-
proved by the regional Ethical Review Board in Stockholm,
Sweden.
Statistical Analyses
Raw scores were generally used in the analyses because the
tests used do not have norms for the entire age range of the
participants (14-26 years). An exception was the vocabulary
test. The raw scores for the WISC and WAIS versions of Vo-
cabulary are not comparable. Scores on the same scale was
achieved by a z-transformation using the means and SDs
from the Swedish norms for WISC and WAIS, respectively.
Comparisons concerning group characteristics (Table I)
were made using Fisher exact test or ANOVA. Differences
in outcome variables were initially tested by comparing the
unexposed and those exposed to 2 or more courses
(Student t test). Outcomes that differed significantly (P <
.05) in the univariate tests were included in a mixed
regression model. This mixed regression model corrects for
age-at-testing, which compensated for the age component
in the raw test scores. Parents’ education, a strong
indicator of socioeconomic status that impacts test score
outcome was also included in the model. To not over
specify the model and given the size of the cohort (n =
102), no further covariates were included. The lack of
independence in multiple gestations was adjusted for as
a random effect in the model. Binary outcome variables
were analyzed using logistic regression. No corrections for
multiple analyses were made. A P value of <.05 (2-sided)
was considered to indicate statistical significance. With our
given sample, we had a power of 0.8 to detect a group
difference of 0.56 or more (ie, medium effect size). TheStalnacke et al
Table I. Maternal, pregnancy, and participant (neonatal and at follow-up) characteristics in relation to number of weekly
courses of antenatal corticosteroids for preterm birth
Unexposed 1 course 2 courses 3 courses 4 or more courses Total P value
Invited n 103 48 26 26 38 241
Participants n 44 25 19 14 25 127
Maternal age (y) 30.5  5.3 28.8  4.8 32.5  5.2 32.5  4.8 31.2  5.2 30.8  5.2 .10
Parental education* .10
High school or less 11 (25.0) 10 (40.0) 8 (42.1) 6 (42.9) 5 (20.0) 40 (31.5)
Professional 6 (13.6) 6 (24.0) 2 (10.5) 3 (21.4) 1 (4.0) 18 (14.2)
Academic 27 (61.4) 9 (36.0) 9 (47.4) 5 (35.7) 19 (76.0) 69 (54.3)
Primipara 21 (47.7) 18 (72.0) 3 (15.8) 7 (50.0) 16 (64.0) 65 (51.2) .003
Multiple pregnancy 9 (20.5) 5 (20.0) 9 (47.4) 9 (64.3) 10 (40.0) 42 (33.1) .009
Maternal smoking 8 (18.2) 7 (28.0) 5 (26.3) 1 (7.1) 4 (16.0) 25 (19.7) .54
Gestational age at first course (wk) - 31.1  1.2 31.2  1.9 29.6  2.1 28.1  1.6 29.7  2.0 <.001
Total betamethasone dose (mg) - 23.2  2.8 35.4  2.0 48.0  0.0 72.4  16.5 45.5  22.6
Gestational age at birth (wk) 34.9  2.9 32.6  2.9 33.7  2.8 32.9  2.3 35.1  2.0 34.0  2.8 .002
Male sex 25 (56.8) 14 (56.0) 11 (57.9) 10 (71.4) 15 (60.0) 75 (59.1) .90
Apgar 5 min <7† 4 (14.3) 3 (13.6) 2 (10.5) 2 (15.4) 0 (0.0) 11 (10.3) .27
Birth weight (g) 2526  686 1888  590 2240  607 2176  622 2381  503 2291  650 .002
Birth weight SDS 0.2  1.0 0.8  1.2 0.3  1.1 0.0  1.1 0.7  1.1 0.4  1.1 .05
Birth weight <10th percentile 8 (18.2) 8 (32.0) 3 (15.8) 3 (21.4) 7 (28.0) 29 (22.8) .63
Major neonatal complicationsz 5 (11.4) 6 (24.0) 1 (5.3) 4(28.6) 2 (8.0) 18 (14.2) .17
Age at follow-up (y) 18.5  2.9 18.0  3.4 18.5  3.5 18.4  2.9 17.0  2.4 18.1  3.0 .37
Handedness, non-right 4 (9.1) 1 (4.0) 2 (10.5) 1 (7.1) 3 (12.0) 11 (8.7) .91
Swedish not first language 5 (11.4) 1 (4.0) 1 (5.3) 0 (0.0) 1 (4.0) 8 (6.3) .71
Glasses or lenses 11 (25.0) 7 (28.0) 9 (47.4) 5 (35.7) 7 (28.0) 39 (30.7) .49
n, number.
Data are mean  SD or numbers (proportion).
*The parent with highest education is represented.
†Missing data, n = 107.
zIncludes at least 1 of the following: mechanical ventilation, neonatal seizures, sepsis, bronchopulmonary dysplasia (defined as need of supplemental oxygen at an age corresponding to 36 ges-
tational weeks), any degree of retinopathy of prematurity, or intraventricular hemorrhage.
August 2013 ORIGINAL ARTICLESstatistical analyses were performed using SPSS Statistics 18
(PASW) and 20 for Windows (SPSS Inc, Chicago, Illinois).
Results
Among the 21 outcome measures viewed as scores represent-
ing performance of executive functions, 4 revealed significant
univariate group differences between unexposed subjects and
subjects exposed to 2 or more courses of antenatal corticoste-
roids (P < .02; t test of mean differences; see Table III). All 4
were found in the domain of attention and speed and
included Symbol Search, Coding, Digit Span Forward, and
Rapid Visual Information Processing. After adjusting for
age-at-testing, level of parental education, and clustering
effects attributable to multiple gestations, only Symbol
Search and Digit Span Forward remained significant; the
other 2 differences were near statistical significance. In
both Symbol Search and Digit Span Forward the difference
was slightly above one-half a SD; a medium effect size.
The additional variance explained in these 2 outcomes by
adding exposure in a multiple regression model was 4%-
6%. In addition, these 2 group differences were not dose-
dependent. In fact, the subgroup exposed to 2 courses had
the lowest means and those exposed to 3 courses the
highest (Table IV).
There were no significant associations between repeat cor-
ticosteroid exposure and verbal or nonverbal ability 14-26
years later (Table III). Memory and learning were also
unrelated to repeat exposure to antenatal corticosteroids.Cognitive Outcome in Adolescents and Young Adults after RepeaEssentially, there were no differences between the repeat
corticosteroid and unexposed groups in scores from self-
report inventories on psychological health. Scores within
the clinical range, in the top 2.5th percentile (sex and age ad-
justed norms), were similar between groups. The group ex-
posed to 2 or more courses reported a significantly lower
rate of being bullied (OR 0.26; P = .003). Self-reported atten-
tion deficit hyperactivity disorder symptoms were not in-
creased with repeat corticosteroid courses. Life satisfaction,
obtained by self-rated quality of life inventory, did not reflect
any differences among groups, or any dose-dependent rela-
tionships.
Discussion
We report the long-term cognitive and behavioral outcome
in adolescents and young adults exposed to repeat courses
of antenatal corticosteroids. We found no indication of ad-
verse effects of this treatment on higher cognitive functions
and behavior. Indeed, there were no significant differences
between the repeat and unexposed groups in their ability to
learn, understand, and manage meaningful material. How-
ever, mean scores obtained on 2 tests, Symbol Search and
Digit Span Forward, were significantly lower for the repeat
group compared with the unexposed group, even after con-
trolling for covariates andmultiple gestations. Bothmeasures
fall within the executive domain of attention and speed,
which reduces the likelihood that they are mere statistical ar-
tifacts attributable to multiple comparisons. These mildt Courses of Antenatal Corticosteroids 443
Table III. Neuropsychological outcomes in 14- to 26-year-old subjects exposed to repeat weekly courses of antenatal
corticosteroids for preterm birth
Unexposed
(n = 44)
Repeat ACS
(n = 58)
P value
t test
Adjusted mean difference
[95% CI] (n =102)
Adjusted
P value
General cognitive ability
Design* 47.7  9.8 46.4  11.5 .54
Vocabulary†, normed z-score 0.19  1.2 0.20  0.99 .96
Memory and learning
RAVLz 54.0  6.6 54.9  7.0 .51
RAVLz Retention 12.5  1.9 12.8  1.8 .43
Working memory
Spatial Working Memoryx, between errors 10.9  8.8 12.6  11.1 .41
Digit Span Backward* 7.0  1.9 6.4  2.0 .11
Attention and speed
RVPx, A’ 0.90  0.05 0.88  0.05 .02 0.02 [0.04 to 0.00] .05
Reaction Timex, 5-choice reaction time 294  33 291  33 .68
Reaction Time, 5-choice movement time 322  112 297  81 .21
Trail Making Test{, 2, digits 28.7  11.1 32.6  12.5 .11
Trail Making Test, 3, letters 28.8  13.4 32.3  13.1 .18
Digit Span Forward* 9.7  1.9 8.7  1.8 .007 0.91 [1.65 to 0.17] .02
Symbol Search* 40.3  6.5 35.8  7.8 .003 3.88 [6.76 to 1.01] .009
Coding* 74.2  13.5 67.1  16.1 .02 5.63 [11.73 to 0.48] .07
Cognitive flexibility and inhibition
Trail Making Test{, 4, switching 64.6  23.5 72.2  21.4 .10
Verbal Fluency{ 1, letters 39.4  11.6 38.0  12.2 .56
Verbal Fluency 2, category 42.6  9.0 42.7  9.2 .95
Verbal Fluency 3, correct 13.3  3.0 13.0  3.1 .59
Verbal Fluency 3, switching 11.5  3.4 10.9  3.7 .35
Design Fluency{1, black 10.4  2.6 10.1  2.7 .56
Design Fluency 2, white 11.9  2.9 11.2  3.1 .26
Design Fluency 3, switching** 8.8  2.7 7.9  2.3 .05
Design Fluency total** 31.1  6.7 29.1  6.7 .15
IEDx, Adjusted errors** 21.6  18.3 26.6  19.4 .19
Stop Signal Taskx, signal stop reaction time** 178  33 190  47 .16
ACS, antenatal corticosteroids; RAVL, rapid visual processing; RVP, Rapid Visual Information Processing; IED, Intra-Extra Dimensional Set Shift.
Data are mean  SD.
Significant mean differences were adjusted for age at testing, level of parental education and clustering effects attributable to multiple gestations.
*From WISC.
†WISC Vocabulary was administered to those born 1992-1996; WAIS Vocabulary to those born 1983-1991.
zRey Auditory Verbal Learning; Retention after 30 min.
xFrom Cambridge Neuropsychological Test Assessment Battery.
{From Delis-Kaplan Executive Function System.
**Adjusted mean difference [95 % CI] (n = 127).
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 163, No. 2deficits did not seem to have an impact on more complex
cognitive task performance, self-reported attention, adapt-
ability, or overall psychological functioning.
The results of this long-term follow-up study are in general
agreement with previous follow-up studies of 2- to 6-year-
old children after repeat courses of antenatal corticoste-
roids.12,13,15 Studies focusing on the preschool years have
not shown any difference between repeat corticosteroid
groups and control groups in general cognitive abilities.
However, they do report effects on attention problems,12 dis-
tractibility, and aggressive behavior.13 Although deficits in
test scores cannot be equated with behavior problems in ev-Table IV. Selected executive function outcomes in 14- to 26-y
courses of antenatal corticosteroids in fetal life
1 course vs unexposed 2 courses vs unexpo
Symbol Search 3.74 [7.22 to 0.25] (0.04) 5.93 [9.83 to 2.02]
Digit Span Forward 0.46 [1.38 to 0.47] (0.33) 1.36 [2.39 to 0.33]
Adjusted mean difference [95% CI] and (adjusted P value) by exposure group compared with unexpose
effects because of multiple gestations.
444eryday life, the modest group differences in test scores ob-
served in our cohort may be functionally related to the
behavior problems found in preschool children. These func-
tional and behavioral alterations could reflect increased sen-
sitivity of certain neural circuits to programming effects by
corticosteroids during fetal life. Recent studies in nonhuman
primates investigating the long-term effects of fetal glucocor-
ticoid overexposure on prefrontal cortex gene expression
have found significant effects of this treatment on the expres-
sion of glucocorticoid receptors. These effects were more
pronounced in neonates than in adults.25 It is tempting to
speculate that the modest effects observed in our cohort ofear-old subjects (n = 127) in relation to number of weekly
sed 3 courses vs unexposed 4 or more courses vs unexposed
(0.003) 1.88 [6.59 to 2.83] (0.43) 3.35 [6.92 to 0.22] (0.06)
(0.01) 0.22 [1.45 to 1.02] (0.73) 0.86 [1.81 to 0.08] (0.07)
d. Mean differences were adjusted for age at testing, level of parental education, and clustering
Stalnacke et al
August 2013 ORIGINAL ARTICLESadolescents and young adults are remnants of deficits that
were more clearly expressed in the younger preschool chil-
dren in previous studies but have been compensated for in
later development.
Findings from animal studies indicate potential detrimen-
tal brain development effects due to repeat exposure of the
fetus to corticosteroids.26,27 In addition, previous studies
have raised the possibility that a threshold effect may exist
concerning the influence of antenatal corticosteroids on
brain development and later-life behavior.13,15 Accordingly,
current guidelines for antenatal corticosteroid treatment
recommend the use of a single course of steroids.2 However,
in our dose-response analysis, we did not find any relation-
ship between the number of corticosteroid courses and
outcome. These findings are reassuring, given the dose-
dependent reduction in neonatal anthropometrics previously
reported to occur in this cohort.16 A caveat exists in the over-
representation of individuals with low birth weight SDS
among nonparticipants; this bias may influence the lack of
association between exposure and outcome.
The strengths of this study include a well-characterized co-
hort with a fairly high gestational age at birth and low neona-
tal morbidity, and a comprehensive long-term follow-up.
Limitations are the small size of our cohort and the observa-
tional study design. Despite the limitations, the sample size
still has acceptable power (0.8) to detect differences of clinical
significance. We cannot exclude that some self-selection bias
in study participation and group differences in gestational
age could also have affected outcome. Betamethasone was
the only corticosteroid evaluated in this study, which is the
case also for the 10 randomized controlled trials included
in the latest Cochrane review.9 Therefore, we do not know
whether exposure to dexamethasone would give similar out-
come. Further, the study does not address the issue of long-
term cognitive outcome in subjects exposed to repeat courses
of antenatal corticosteroids and born before 28 weeks of ges-
tation; a group that today shows high survival, partly attrib-
utable to the use of antenatal corticosteroids.28 This
extremely preterm group would most likely benefit from re-
peat courses of antenatal corticosteroids and because the sen-
sitivity of the fetal brain changes during development,11 it is
feasible that exposure earlier in fetal life could have a different
outcome. For this group, the long-term neurodevelopmental
effects remain unknown. The absence of major pregnancy
and neonatal complications in our group, most of them
born moderately preterm or at term, rather makes it possible
to disclose effects of antenatal corticosteroids exposure per
se, without significant interference from severe maternal
and perinatal morbidity or postnatal steroid exposure.
The results of the present study indicate that repeat expo-
sure to antenatal corticosteroids may have an impact on as-
pects of executive function. However, these effects were not
associated with deficits in higher cognitive functions or psy-
chological health and should be weighed against the well
documented treatment benefits on neonatal health. To finally
fill the present gap in knowledge—whether and how antena-
tal corticosteroids may affect long-term development—weCognitive Outcome in Adolescents and Young Adults after Repeawill have to wait another decade, when children from previ-
ous randomized controlled studies have become young
adults.7,12,15 n
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Table II. Nonparticipant characteristics (maternal, pregnancy, and neonatal) in relation to number of courses of
antenatal corticosteroids and compared with participants
Unexposed 1 course 2 courses 3 courses
4 or more
courses
Total
(nonparticipants)
Total
(participants)
P
value*
Invited n 103 48 26 26 38 241 241
Nonparticipants n 59 23 7 12 13 114 127
Maternal age (y) 30.6  5.2 29.9  5.3 29.2  5.6 31.9  8.0 30.9  3.7 30.5  5.4 30.8  5.2 .67
Primipara 28 (47.5) 15 (65.2) 4 (57.1) 8 (66.7) 7 (53.8) 62 (54.4) 65 (51.2) .70
Multiple pregnancy 12 (20.3) 6 (26.1) 1 (3.4) 4 (33.3) 6 (46.2) 29 (25.4) 42 (33.1) .21
Maternal smoking† 16 (30.2) 6 (30.0) 3 (42.9) 1 (9.1) 0 (0.0) 26 (25.2) 25 (19.7) .34
Gestational age at first course (wk) 31.1  1.4 30.1  2.0 29.1  2.0 27.6  1.6 29.7  2.1 29.7  2.0 .99
Total betamethas1 dose (mg) - 24.0  0.0 37.1  5.0 48.0  0.0 70.1  11.8 41.1  19.3 45.5  22.6 .32
Gestational age at birth (wk) 34.5  2.9 33.2  2.5 36.6  3.7 34.5  3.1 34.2  3.6 34.3  3.0 34.0  2.8 .48
Male sex 43 (72.9) 5 (65.2) 4 (57.1) 8 (66.7) 9 (69.2) 79 (69.3) 75 (59.1) .11
Apgar 5 min <7z 2 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.7) 3 (3.3) 11 (10.3) .09
Birth weight (g) 2377  736 2009  500 2881  715 2210  599 2050  773 2274  705 2291  650 .85
Birth weight SDS 0.6  1.1 0.9  1.1 0.3  1.0 1.0  1.3 1.5  1.9 0.8  1.3 0.4  1.1 .03
Birth weight < 10th percentile 15 (25.4) 7 (30.4) 1 (14.3) 6 (50.0) 7 (53.8) 36 (31.6) 29 (22.8) .15
Major neonatal complicationsx 5 (8.5) 6 (26.1) 0 (0.0) 0 (0.0) 2 (15.3) 13 (11.4) 18 (14.2) .57
Data are mean  SD or numbers (proportion).
*P value compares all participants against all nonparticipants.
†Missing data, n = 103.
zMissing data, n = 90.
xIncludes at least one of the following: mechanical ventilation, neonatal seizures, sepsis, bronchopulmonary dysplasia (defined as need of supplemental oxygen at a gestational age of 36 weeks), any
degree of retinopathy of prematurity, or intraventricular hemorrhage.
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